Research programme: tetracycline compounds - Tetraphase Pharmaceuticals
Alternative Names: TP-038; TP-120; TP-2191; TP-2758; TP-2910; TP-3263; TP-333; TP-4607; TP-4622; TP-5336; TP-7269; TP-8060; TP-834; TP-837Latest Information Update: 30 Jul 2020
At a glance
- Originator Tetraphase Pharmaceuticals
- Class Anti-infectives; Antibacterials; Tetracyclines
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Community-acquired pneumonia; Urinary tract infections
Most Recent Events
- 28 Jul 2020 Tetraphase Pharmaceuticals has been acquired by La Jolla Pharmaceutical Company
- 28 Jul 2018 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
- 24 Jul 2016 Preclinical development is ongoing for Bacterial infections in USA